Park MK - Search Results

1

The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.

Jeong SI, Ban MS, Hwang JG, Park MK, Lim S, Kim S, Kwon SK, Kim Y, Cho JM, Na JJ, Huh W, Chung JY. Jeong SI, et al. Among authors: park mk. Diabetes Obes Metab. 2024 Jul;26(7):2588-2597. doi: 10.1111/dom.15573. Epub 2024 Apr 15. Diabetes Obes Metab. 2024. PMID: 38618974 Clinical Trial.

2

Influence of Renal Function on the Single-Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection.

Hwang JG, Kim YK, Choi YS, Kwon SK, Han JH, Park MK. Hwang JG, et al. Among authors: park mk. J Clin Pharmacol. 2022 Jan;62(1):46-54. doi: 10.1002/jcph.1945. Epub 2021 Sep 17. J Clin Pharmacol. 2022. PMID: 34327707 Clinical Trial.

3

Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects.

Park SR, Hwang JG, Jeong SI, Choi YS, Min HJ, Kim HY, Choi BH, Park MK. Park SR, et al. Among authors: park mk. Transl Clin Pharmacol. 2024 Mar;32(1):63-72. doi: 10.12793/tcp.2024.32.e6. Epub 2024 Mar 26. Transl Clin Pharmacol. 2024. PMID: 38586120 Free PMC article.

4

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.

Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS. Cha YJ, et al. Among authors: park mk. Drug Des Devel Ther. 2014 Sep 26;8:1613-9. doi: 10.2147/DDDT.S65596. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25302016 Free PMC article. Clinical Trial.

5

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects.

Son YJ, Park MK, Park HJ, Kim HY, Jang YL, Choi YS, Hwang JG, Seo JH, Kim YK. Son YJ, et al. Among authors: park mk, park hj. Pharmaceutics. 2023 Apr 19;15(4):1280. doi: 10.3390/pharmaceutics15041280. Pharmaceutics. 2023. PMID: 37111764 Free PMC article.

6

Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject.

Hwang JG, Jeong SI, Kim YK, Lee Y, Ji SC, Lee S, Park MK. Hwang JG, et al. Among authors: park mk. Transl Clin Pharmacol. 2022 Dec;30(4):212-225. doi: 10.12793/tcp.2022.30.e23. Epub 2022 Dec 26. Transl Clin Pharmacol. 2022. PMID: 36632075 Free PMC article.

7

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.

Yu KS, Kim B, Shin D, Park MK, Hwang JG, Kim MG, Chung H, Ghim J, Chung JY, Smolen JS, Burmester GR, Kim S, Bae Y, Jeon D, Yoo J, Yang G, Bae J, Keystone E. Yu KS, et al. Among authors: park mk. Expert Opin Investig Drugs. 2023 May;32(5):429-439. doi: 10.1080/13543784.2023.2212155. Epub 2023 May 26. Expert Opin Investig Drugs. 2023. PMID: 37231670 Clinical Trial.

8

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.

Kim TE, Lim KS, Park MK, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Kim TE, et al. Among authors: park mk. Clin Ther. 2012 Sep;34(9):1986-98. doi: 10.1016/j.clinthera.2012.08.006. Epub 2012 Sep 1. Clin Ther. 2012. PMID: 22943970 Clinical Trial.

9

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS. Gu N, et al. Among authors: park mk. Drug Des Devel Ther. 2014 Oct 6;8:1709-21. doi: 10.2147/DDDT.S65678. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25336915 Free PMC article. Clinical Trial.

10

No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.

Kim YK, Hwang JG, Park MK. Kim YK, et al. Among authors: park mk. Drug Des Devel Ther. 2021 Apr 28;15:1725-1734. doi: 10.2147/DDDT.S302215. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33953542 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,057 results

Search Page